Omecamtiv mecarbil (OM) is a myosin activator agent developed for the treatment of heart
failure. OM was reported to increase left ventricular ejection fraction and systolic ejection …

Despite recent advances in chronic heart failure (HF) management, the prognosis of HF
patients is poor. This highlights the need for researching new drugs targeting, beyond …

Heart failure (HF) is a major public health problem in the United States as well as worldwide.
Chronic heart failure is a syndrome of reduced cardiac output resulting from impaired …

Aims Heart failure with reduced ejection fraction (HFrEF) is a disease with high mortality and
morbidity. Recent positive inotropic drug developments focused on cardiac myofilaments …

Aims Colour tissue Doppler imaging (TDI) M‐mode through the mitral leaflet is an easy and
precise method to obtain cardiac time intervals including isovolumic contraction time (IVCT) …

Heart failure (HF) is a rapidly growing pandemic while medical treatment options remain
limited. Omecamtiv mecarbil (OM) is a novel HF drug that directly targets the myosin heads …

Abstract Purpose of Review Cardiac myosin inhibitors (CMIs) and activators are emerging
therapies for hypertrophic cardiomyopathy (HCM) and heart failure with reduced ejection …

Abstract Aims In GALACTIC-HF, the cardiac myosin activator omecamtiv mecarbil compared
with placebo reduced the risk of heart failure events or cardiovascular death in patients with …

Heart failure is a syndrome that can result from impaired heart muscle contractions like in
dilative cardiomyopathy but also from hypertrophic obstructive cardiomyopathy (HOCOM). A …

Abstract Effects of non-cardiac drugs on cardiac contractility can lead to serious adverse
events. Furthermore, programs aimed at treating heart failure have had limited success and …